Cigna Corporation (CI) - Stock Analysis

Business Model

25%

3.3/5

3.31

Evernorth's multi-year PBM contracts anchor revenue on a sticky institutional base, while Cigna Healthcare's commercial insurance renews annually with moderate employer retention. Geographic concentration is almost entirely domestic, limiting the buffer from international diversification. Stop-loss business volatility tempers the overall predictability of the model.

Sub-dimension

Summary

Score

Revenue Predictability30%

3.75

Forward visibility of revenue: backlog, contracts, retention

3.75

Summary

Express Scripts under Evernorth serves over 118 million pharmacy lives under multi-year agreements, including a five-year contract with Centene covering approximately 20 million beneficiaries beginning January 2024. Consolidated revenue grew in each fiscal year from FY2022 through FY2025, including through the 2022 inflation period.

3.75

Product Diversification10%

2.75

Diversification across product lines, segments, and customers

2.75

Summary

Evernorth Health Services generates roughly 75-80% of consolidated revenue, with Cigna Healthcare comprising most of the remainder, and both segments operate within the healthcare sector with correlated cost pressures. The 2025 sale of the Medicare Advantage business to HCSC further concentrated the portfolio.

2.75

Geographic Diversification15%

1.75

Distribution across regions and home-market dependence

1.75

Summary

Nearly all consolidated revenue is derived from U.S. customers, with the international health solutions segment representing a small fraction of total revenues. The 2025 sale of Medicare Advantage further reduced any diversification offset, leaving the company almost entirely exposed to U.S. healthcare policy and reimbursement dynamics.

1.75

Scalability20%

3.25

Ability to grow revenue without proportional cost increases

3.25

Summary

The PBM platform processes pharmacy claims with limited incremental cost, and the Centene relationship expanded Evernorth's pharmacy lives from 99 million to 118 million in FY2024 with contained operating expense growth. Healthcare insurance claims, however, scale nearly one-for-one with member volume.

3.25

Revenue Quality25%

3.75

Nature of the revenue: contractual vs transactional, defensive vs discretionary

3.75

Summary

PBM contracts with health plans and employers are multi-year, mission-critical, and embedded in clients' benefits administration infrastructure, providing a durably recurring revenue base. The February 2026 FTC settlement requiring a shift from spread pricing toward cost-plus reimbursement represents a structural change to how Evernorth monetizes the pharmacy benefit.

3.75

Competitive Advantages

40%

The competitive moat is narrow and under structural pressure. Evernorth's position as the largest U.S. PBM by prescription volume provides negotiating scale, but the FTC settlement's mandate to eliminate spread pricing materially reduces one of the primary profit levers. Switching costs are real but surmountable, as demonstrated by the Centene migration from CVS Caremark, and no durable patent or network-effects moat exists across the PBM or commercial insurance businesses.

Pro dimensions

Competitive Advantages · Management · Risk Assessment